7 news items
Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
ITCI
8 Aug 24
:Intra-Cellular Therapies, Inc.Juan Sanchez, M.D.Vice President, Corporate Communications and Investor Relations
Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer
ITCI
7 Aug 24
Communications and Investor Relations646-440-9333 Burns McClellan, Inc.Cameron Radinovic
Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
ITCI
7 Aug 24
Therapies, Inc.Juan Sanchez, M.D. Vice President, Corporate Communications and Investor Relations646-440-9333
A Closer Look at 11 Analyst Recommendations For Intra-Cellular Therapies
ITCI
22 Jul 24
, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
ITCI
18 Jun 24
Therapies, Inc. Juan Sanchez, M.D. Vice President, Corporate Communications and Investor Relations646-440-9333
hzz6udptcc36zho9s
ITCI
12 Jun 24
, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Intra-Cellular Therapies compared
9irg7x9iumn66turfgn037hqexv6p0 o5zicba5ynl1p81serltxi5xehdc3
ITCI
10 Jun 24
-Cellular Therapies, Inc.Juan Sanchez, M.D.Vice President, Corporate Communications and Investor Relations646-440-9333
- Prev
- 1
- Next